Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma

Autor: Laurence Legros, Alina Pascale, Catherine Guettier, Pirayeh Eftekhari, Yasmina Ben Merabet, Maryse Stang, Rachel Bossevot, Emma Goldschmidt, Ayhan Ulusakarya, Stephane Morisset, Maïté Lewin, Didier Samuel, Olivier Rosmorduc
Rok vydání: 2023
Předmět:
Zdroj: Cancer Chemotherapy and Pharmacology. 91:337-344
ISSN: 1432-0843
0344-5704
Popis: Purpose This manuscript reports on the occurrence of early and frequent erythrocytosis in advanced hepatocellular carcinoma (HCC) patients treated with lenvatinib. Methods A cohort of 23 patients with advanced HCC, treated with this antiangiogenic drug for at least one month, was retrospectively analyzed. Results These patients (82.7% men, median age 58.3, cirrhosis in 60.8%) were treated between October 2019 and September 2020 with lenvatinib, as first-line systemic therapy for 82.6% of them. For 20 patients (87%), an early and significant increase in hemoglobin (Hb) level, up to 1.41 g/dL (p 16.5 g/dL), 7 were treated with low-dose aspirin for primary thromboprophylaxis and 2 needed phlebotomy. None underwent thromboembolic complications. A significant Hb decrease was observed after treatment discontinuation (p Conclusion This report documents the frequent occurrence of erythrocytosis during lenvatinib treatment for advanced HCC, likely secondary to EPO secretion by tumor cells through the antiangiogenic activity levatinib. An early and close monitoring of hematologic parameters is, thus, recommended, together with thromboprophylaxis by low-dose aspirin and phlebotomy in case of symptomatic erythrocytosis.
Databáze: OpenAIRE
Externí odkaz: